← Back to Torch Briefings

Managing High-Cost Claimants in a Group Health Captive for the 2027 Renewal

Published by Ryan Mefford | October 12, 2026 | Part of the Torch Briefings series

For a self-funded employer heading into the 2027 plan year, the renewal no longer turns on the broad trend line. It turns on a handful of names. Tokio Marine HCC’s 2026 market report found that medical stop-loss claims exceeding the specific deductible by at least $2 million have risen 213% since 2020, while claims above $500,000 are up 114% over the same period. QBE’s accident & health analysis put the frequency of million-dollar claims at double its 2020 level. The arithmetic is unforgiving: a single claimant can now carry more weight than the rest of a plan combined, and the stop-loss carrier knows it.

A laser is a renewal instrument, not a verdict. When a carrier identifies a plan member with a known, ongoing high-cost condition, it can raise that individual’s specific deductible well above everyone else’s — a “laser.” A member running a $50,000 specific deductible might be lasered to $200,000, leaving the employer to fund the gap out of its own cash flow. The alternative is a no-new-laser renewal, which protects the plan from fresh lasers but typically arrives with a rate cap and a materially higher premium. For a standalone employer, both paths lead to the same place: the volatility of one person’s illness lands squarely on one balance sheet.

Specific and aggregate stop-loss do different jobs. Specific stop-loss protects the plan against an unusually large claim from a single individual, reimbursing losses above the specific deductible. Aggregate stop-loss caps the plan’s total liability across all members in a year — sometimes called sleep insurance — and responds only when the group’s combined claims run past an expected threshold, generally 125% of projected. The two layers answer different fears: one catastrophic outlier, versus a bad year across the whole population.

Between those two sits a quieter lever: the aggregating specific. An aggregating specific deductible is an optional feature in a stop-loss contract under which the employer agrees to retain an additional, defined band of claims above its specific deductible before reimbursement begins. In exchange for carrying that band, the premium comes down. It is, in effect, a disciplined, intentional retention of risk the employer has decided it can fund — and it is precisely the kind of layer a captive is built to hold.

Captive ownership changes who sits across the table. In a group medical captive, a dozen or more mid-market employers co-own the layer of risk that sits above their individual specific deductibles and below the point where the excess carrier takes over — the structure practitioners describe as “me, us, and them.” Each employer keeps its own deductible (me). The captive pools a shared layer above it (us). The excess carrier covers true catastrophe (them). When a laser would otherwise fall on one member, the captive funds the gap across the membership, so the cost of a single claimant is spread rather than concentrated. Ownership also reshapes the submission itself: the pooled claims data is more credible to the carrier, and the members — as owners — see the underlying numbers and share in favorable results instead of surrendering them.

This is where year-over-year volatility is tamed. Discipline at the deductible is measurable. Tokio Marine HCC found that groups raising their specific deductible across four consecutive renewals averaged 2% annual rate increases, against 11% for groups that never moved it. Inside a captive, that discipline is a shared decision rather than a concession extracted at renewal. Lasers can be handled on entry and released at later renewals — funding reserves against a known claimant while the risk is still priced, rather than scrambling when it surfaces. Quota-share allocation assigns the cost of known claimants by tier, so the employers with the heaviest exposure carry the larger share and the rest are insulated.

None of this makes the 2027 trend line disappear. Segal’s projection for 2027 puts medical trend at 9.9% — a 15-year high — with prescription-drug trend at 11.5%, led by specialty and GLP-1 utilization. New cell-and-gene therapies continue to surface million-dollar claims; a spinal muscular atrophy gene therapy approved in late 2025 is one more line item underwriters now watch. The captive does not repeal that math. What it changes is ownership of the response — whether a catastrophic claimant is a crisis that redraws one employer’s renewal, or a funded, anticipated event absorbed by a pool the employer helped build.

That is the work our 4-Step Strategic Process is built to do. Strategic Discovery surfaces the hidden claimants and contract terms already shaping your renewal; Risk Assessment illuminates which layers you should own and which you should transfer; Solution Design crafts the deductible, aggregating-specific, and captive structure around that answer; and Ongoing Optimization keeps the laser conversation, the reserves, and the stop-loss submission under your control year after year. The torch is not in finding a lower number for 2027. It is in deciding, deliberately, who carries the claims you can already see coming.

Explore the PFTN Network

Captive insurance knowledge and expertise across multiple industries and sectors:

PFTN Risk

Risk management and captive insurance foundations

Contractors PFTN

Captives for construction and trade contractors

GovCon PFTN

Captive solutions for government contractors

Nonprofit PFTN

Risk management strategies for nonprofits and associations